CD274 and cervical carcinoma: An analysis of data from two trials (NCT02517398/NCT03427411) provided encouraging outcomes for the use of bintrafusp alfa (anti-TGF-ß/PD-L1 bispecific antibody) in advanced cervical cancer, with 30% (10/33) of patients having a clinical response (66).